adh 1

ADH-1 trifluoroacetate (Exherin trifluoroacetate) is a cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis.

ADH-1 (Exherin) is an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion with potential antineoplastic and antiangiogenic activities.

(-)-OPC-51803 is an antidiuretic hormone V2 receptor agonist used in the treatment of nocturia and urinary incontinence.

(Z)-Leukadherin-1 (ADH-503 free base) is an allosteric agonist of CD11b.

1. Aloenin (Aloenin A) and aloe-emodin are active principles for inhibition of c-ADH and c-ALDH activities in vitro.

ADH-6 TFA, a tripyridylamide compound, effectively disrupts the self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD, thereby targeting and disassociating mutant p53 aggregates in human cancer cells. This action restores the transcriptional activity of p53, resulting in cell cycle arrest and apoptosis. Consequently, ADH-6 TFA holds potential for cancer research [1].

Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)), is a nine-amino acid neuropeptide produced by the posterior pituitary gland. It plays a crucial role in maintaining fluid balance, osmolality, and cardiovascular function through interaction with three distinct G-protein coupled receptors (GPCRs): Avpr1a (V1a), Avpr1b (V1b), and Avpr2 (V2). Argipressin (diacetate) also influences centrally regulated metabolic processes, highlighting its significance in physiological regulation [1].